Lipitor Lawsuit News: Bernstein Liebhard LLP Notes Release of Study Suggesting High Potency Statins May Increase Type 2 Diabetes Risk

Share Article

The Firm is evaluating Lipitor lawsuits on behalf of patients who allegedly developed Type 2 diabetes due to their use of the statin medication.

Free Case Review
These findings echo the allegations regarding the use of Lipitor and diabetes that have been put forth in hundreds of lawsuits currently pending in the U.S.

As Lipitor lawsuit claims ( involving allegations that the popular statin drug causes Type 2 diabetes continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that a newly-released study has found that high-potency doses of Lipitor and other statins may increase the risk for the disease. According to a report from, the authors of the study analyzed records on more than 136,000 patients in Canada, the U.S. and the U.K., two-thirds of whom received high-potency statins. These included patients treated with more than 10mg of rosuvastatin, sold as Crestor, 20mg of atorvastatin, sold as Lipitor, or 40mg of simvastatin, sold as Zocor. The findings suggested that patients in the high-potency group had a 15 percent relative increase in risk of diabetes over two years compared to patients on lower doses.*

“These findings echo the allegations regarding the use of Lipitor and diabetes that have been put forth in hundreds of lawsuits currently pending in the U.S.,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit consultations to anyone who may have been harmed by this medication.

Lipitor Lawsuits
Court records indicate that more than 700 Lipitor lawsuits have been filed in courts around the country on behalf of individuals who developed Type 2 diabetes following treatment with the statin medication. The majority of these claims are pending in a multidistrict litigation now underway in U.S. District Court, District of South Carolina. The Court is currently in the process of selecting individual Lipitor lawsuits for the proceeding’s first bellwether trials, which are likely to begin on or after July 1, 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

According to court documents, Lipitor diabetes claims have been mounting since January 2012, after a study published in JAMA: Internal Medicine reported that post-menopausal women treated with statins may be at an increased risk for developing the disease.** The following month, the U.S. Food & Drug Administration (FDA) mandated that the manufacturers of statins, including Lipitor, add new information to the drugs’ labels regarding this potential risk. However, plaintiffs in Lipitor lawsuits claim that the new information added to the Lipitor label following the FDA’s mandate continues to be inadequate.

Alleged victims of Lipitor and diabetes may be entitled to compensation for medical bills, lost wages, and pain and suffering. Learn more about the side effects that may be associated with Lipitor at Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.

*,, May 29, 2014
**, JAMA Internal Medicine, January 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993? As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website